Literature DB >> 19669167

C1q nephropathy in a child presenting with recurrent gross hematuria.

Luke Taggart1, Alexis Harris, Samir El-Dahr, Franca Iorember.   

Abstract

C1q nephropathy is a rare glomerular disease characterized by mesangial immune deposits with dominant or codominant staining for C1q. The exact pathogenesis leading to the mesangial immune deposits of C1q remains unknown. C1q nephropathy often presents with proteinuria in the nephrotic range, with an unpredictable or poor response to corticosteroid therapy. It is seen more commonly in older children and young adults and is more common in African Americans compared with Caucasians. We present a 4-year-old African American girl who presented with recurrent gross hematuria in the absence of proteinuria or hypertension and whose renal biopsy demonstrated dominant mesangial deposits of C1q. We conclude that C1q nephropathy should be considered in patients who present with recurrent gross hematuria.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19669167     DOI: 10.1007/s00467-009-1290-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  C1q nephropathy: a pediatric clinicopathologic study.

Authors:  S S Iskandar; M C Browning; W B Lorentz
Journal:  Am J Kidney Dis       Date:  1991-10       Impact factor: 8.860

2.  C1q nephropathy with asymptomatic urine abnormalities.

Authors:  Masashi Nishida; Hidekazu Kawakatsu; Yasuko Okumura; Kenji Hamaoka
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

3.  C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis.

Authors:  T Srivastava; V Chadha; E M Taboada; U S Alon
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

4.  C1q nephropathy in association with Gitelman syndrome: a case report.

Authors:  Coral Hanevold; Ayesa Mian; Rory Dalton
Journal:  Pediatr Nephrol       Date:  2006-09-06       Impact factor: 3.714

5.  Distinguishing C1q nephropathy from lupus nephritis.

Authors:  Andrew Sharman; Peter Furness; John Feehally
Journal:  Nephrol Dial Transplant       Date:  2004-03-05       Impact factor: 5.992

6.  C1q nephropathy: a variant of focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Joshua A Schwimmer; M Barry Stokes; Samih Nasr; Robert L Seigle; Anthony M Valeri; Vivette D D'Agati
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

7.  A single-center study of C1q nephropathy in children.

Authors:  Isabel Roberti; Noosha Baqi; Shefali Vyas; Dae Un Kim
Journal:  Pediatr Nephrol       Date:  2008-08-08       Impact factor: 3.714

8.  Clinicopathologic correlation of C1q nephropathy in children.

Authors:  Yuko Fukuma; Satoshi Hisano; Yoshie Segawa; Kazuhiko Niimi; Noboru Tsuru; Yoshitsugu Kaku; Ken Hatae; Yasuhiro Kiyoshi; Akihisa Mitsudome; Hiroshi Iwasaki
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

9.  C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome.

Authors:  J C Jennette; C G Hipp
Journal:  Am J Kidney Dis       Date:  1985-08       Impact factor: 8.860

10.  Pathology, clinical presentations, and outcomes of C1q nephropathy.

Authors:  Alenka Vizjak; Dusan Ferluga; Mojca Rozic; Anastazija Hvala; Jelka Lindic; Tanja Kersnik Levart; Vesna Jurcić; J Charles Jennette
Journal:  J Am Soc Nephrol       Date:  2008-07-23       Impact factor: 10.121

View more
  2 in total

Review 1.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

2.  C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.

Authors:  Kipyo Kim; Hyung-Eun Son; Ji-Young Ryu; Hajeong Lee; Seung Hyeok Han; Dong-Ryeol Ryu; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin; Se Won Oh
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.